Committee advances medical-psilocybin bill after hours of testimony from veterans, clinicians and advocates

Senate Bill 219, which would establish a regulated medical-psilocybin program for a limited set of qualifying conditions, advanced from the committee after prolonged testimony by veterans, clinicians, hospice providers and academic researchers.

What the bill would do: The bill authorizes a Department of Health-administered program for medically supervised psilocybin-assisted therapy limited initially to treatment‑resistant major depressive disorder, post-traumatic stress disorder, certain substance‑use disorders and end‑of‑life anxiety. The program would be implemented by the Department of Health under rules to be adopted in collaboration with an advisory board; the bill establishes an advisory board and a research/equity fund structure. The statute, as amended in committee, removes a direct appropriation in the bill (the sponsor said funding was included in the executive budget) and adds a veteran member to the advisory board.

Testimony and concerns: Dozens of witnesses — including veterans and first responders who reported that psilocybin therapy had been life-changing in out-of-state or research settings, clinicians who treat trauma and hospice physicians — urged passage. Witnesses cited research from Johns Hopkins, NYU and other academic centers and described durable clinical benefits in some trials.

Committee questions focused on clinical protocols, clinician qualifications, safety and dosage. Members asked whether synthetics or pharmaceutical-grade psilocybin would be included; sponsors said the program targets the natural psilocybin product and that FDA‑approved products are handled separately. Some senators urged that clinician qualifications, training requirements, and precise clinical protocols be specified or delegated to the Department’s rulemaking. The bill delays program start and requires the department to develop rules; the transcript notes a statutory milestone that the department would not begin program administration until 12/31/2027 to allow time for rulemaking and program design.

Liability and criminal-exposure language: Committee debated language that would shield participating clinicians from arrest or prosecution for activities authorized by the act while preserving civil liability for negligent care. The committee adopted a drafting change to make clear clinicians would not be prosecuted criminally for activities authorized by the statute, while committee members asked the sponsor to tighten language so clinicians remain accountable for negligent or unlawful conduct.

Outcome: After adoption of a technical amendment (striking an appropriation and adding a veteran to the advisory board) the committee voted to advance a committee substitute for further work; sponsors emphasized that rulemaking and program design were to be done by the Department of Health before any clinical operations began.

Provenance: Sponsor presentation, extended public testimony, and member questioning are recorded across the transcript block on SB219.